In brief, chemotherapy-induced alopecia affects up to 65% of cancer patients receiving systemic chemotherapy and is consistently rated among the most distressing treatment side effects, contributing to treatment refusal in a meaningful proportion of cases. Sight index equals sign, 30 to 1 inches. Scalp cooling has emerged as the only evidence-based intervention to reduce hair loss during chemotherapy. A Springer Nature review published April 2026 confirmed this status. A randomized controlled trial from Peking University Cancer Hospital, 152 patients published April 2, 2026, compared machine-based and chemical cooling systems. A JAMA Network Open Study from January 2026 found significant racial disparities in persistent CIA. This article covers the mechanism, the 2026 evidence, who benefits most and what the recovery timeline looks like. Chemotherapy-induced hair loss is different from every other hair loss type covered in this series in one critical way. The cause is known, the timeline is predictable, and for most people it is temporary. What is poorly communicated in most clinical settings is the mechanism, the options for reducing it, and the honest limitations of those options. This article addresses that gap. The cold results in local vasoconstriction, which potentially minimizes the amount of cytotoxic drug that reaches the cells of the hair follicles. The mechanism depends on the specific chemotherapy agent, taxanes, paclataxel and dositaxyl taxanes cause hair loss by disrupting microtubule formation in dividing cells, including hair matrix cells. The onset is rapid, often within the first two weeks of treatment, and the loss can be complete. Taxane-based regimens are also the chemotherapy type, where scalp cooling shows its most consistent evidence of benefit, making taxane selection one of the key variables in whether scalp cooling is appropriate. Anthrocyclines, doxorubicin, AC regimen. Anthrocyclines cause hair loss through DNA intercalation and topoisomerase inhibition in dividing cells. The AC regimen, doxorubicin plus cyclophosphamide, is particularly associated with severe and rapid hair loss. Scalp cooling is less effective with anthracycline-based regimens than with taxanes. The drug's mechanism and distribution characteristics make vasoconstriction less able to reduce follicle exposure. A 2026 Memorial Sloan Kettering Clinical Trial, NCT0180579 currently active, is in V, stygating lower scalp cooling temperatures specifically for AC-based regimens, targeted therapies and immunotherapy, different patterns, not all systemic cancer treatments cause the classic CIA pattern. A 2025 Journal of Clinical Oncology Study, Salehi et al. assessed scalp cooling in patients receiving trestuzumab deruxtakin, TDXD, for metastatic breast cancer, an antibody drug conjugate with a different mechanism from traditional chemotherapy. The CIA pattern and scalp cooling response in newer targeted agents is still being characterized. Scalp cooling variability in efficacy depending on application system, patient factors, and assessment tools is an important consideration when evaluating whether scalp cooling is appropriate for a specific treatment regimen. This decision should involve the treating oncologist. How does scalp cooling work and what does the 2026 evidence show? Scalp cooling reduces the temperature of the scalp to approximately 18 to 22 degrees Celsius during chemotherapy infusion and for a defined period before and after. The cold results in local vasoconstriction, which potentially minimizes the amount of cytotoxic drug that reaches the cells of the hair follicles. It is applied for up to an hour before, during, and up to seven hours after each chemotherapy session, depending on the chemotherapy regimen and cooling system. The April 2026 RCT from Peking University Cancer Hospital, published in the Breast A Prial 2 2026, is the most recent large randomized trial. A prospective randomized trial of 152 patients with early breast cancer compared a machine-based scalp cooling system against a chemical cooling cap. Allopecia was assessed using the WHO toxicity grading scale. Quality of life and psychological status were evaluated using the EORTC QLQC30 and the hospital anxiety and depression scale. Both systems reduced CIA relative to no cooling, with the machine-based system generally showing more consistent temperature maintenance. A November 2025 systematic review, Lambert A., Ohio State University Support Care Cancer, specifically addressed variability in scalp cooling duration and efficacy. Chemotherapy-induced alopecia is a distressing side effect. Scalp cooling therapy reduces the risk of CIA, but variability in pre- and post-infusion cooling durations limits consistent outcomes. Standardization of cooling protocols is needed. Up to 65% of cancer patients experience CIA, one of the most distressing side effects and a significant factor in treatment refusal rates, particularly in women with early-stage breast cancer, 18 to 22 degrees Celsius, target scalp temperature during scalp cooling. The local vasoconstriction at this temperature reduces drug delivery to follicle cells sufficiently to prevent or reduce CIA in taxane based regimens. Only evidence based non pharmacological intervention for CIA, confirmed by the Springer Nature April 2026 review, no PE.